Theravance Inc., of South San Francisco, will use proceeds of a $250 million aggregate principal amount of convertible subordinated notes due 2023 to make milestone payments to GlaxoSmithKline plc upon launch of products developed under the two companies' collaboration around long-acting beta 2 agonists (LABAs).